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Objective: We investigated the effects of celecoxib, diclofenac, and ibuprofen on the disease-speciﬁc
quality of life, synovial ﬂuid cytokines and signal transduction pathways in symptomatic knee osteoar-
thritis (OA).
Design: Ninety patients scheduled for a total knee arthroplasty (TKA) were randomized to six groups that
were treated with low and high dosages of celecoxib, diclofenac or ibuprofen. At the time of the ﬁrst
admission (T0) and at surgery (T1 ¼14 days after beginning of the nonsteroidal anti-inﬂammatory drugs
(NSAIDs)), samples of knee synovial ﬂuid were obtained from each patient for analysis. During the
surgery the synovial tissue was harvested from the knee of patients. The Western Ontario and McMaster
universities (WOMAC) score was used to evaluate the patient disease-speciﬁc quality of life at T0 and T1.
Microarray tests performed at T0 and T1 were used to evaluate the effects of NSAIDs on Tumor necrosis
factor (TNF)-alpha, Interleukin-6 (IL-6), IL8 and Vascular endothelial growth factor (VEGF) concentration
in the synovial ﬂuid. Western blot assays evaluated the effects of NSAIDs on MAP kinase (MAPK) signal
transduction pathway in the synovial membrane.
Results: NSAID treatment induced a statistically signiﬁcant improvement in the WOMAC score and a
statistically signiﬁcant decrease in the IL-6, VEGF and TNF-alpha concentration in the synovial ﬂuid.
Higher dosages of NSAIDs provided a greater improvement in the disease-speciﬁc quality of life of pa-
tients and lower concentrations of pro-inﬂammatory cytokines in the synovial ﬂuid. Inhibition of MAPKs
was noted after NSAID treatment.
Conclusion: Short-term NSAID treatment improves the patient disease-speciﬁc quality of life with a
parallel decrease in pro-inﬂammatory synovial ﬂuid cytokine levels in knee OA. Signal transduction
pathways may be involved in regulating the anti-inﬂammatory effects of NSAIDs.
ClinicalTrial.gov: NCT01860833.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.: O. Galasso, Department of
e, Magna Græcia University,
: 39-0961-3647662; Fax: 39-
s Research Society International. PIntroduction
Central mechanisms may play a role in pain perception during
osteoarthritis (OA). However, local inﬂammation (which involves
production of pro-inﬂammatory cytokines such as interleukin (IL)
Tumor necrosis factor (TNF)-alpha, Interleukin-6 (IL-6) and IL-8) is
considered to be amajor source of pain. In addition to their role in the
pathomechanisms of osteoarthritic pain, synovial ﬂuid cytokinesublished by Elsevier Ltd. All rights reserved.
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nociception1. Several cytokines have been detected in the synovial
ﬂuid of patients with early OA2. Among these, TNF-alpha and IL-6
were found in 96.1% and 84.6% of OA synovial ﬂuid samples,
respectively3. TNF-alpha is the major pro-inﬂammatory cytokine
responsible for the shift of cartilage homeostasis towards more
catabolism and degradation of the cartilage4. In details, it activates
sensory neurons directly via its receptors5, increases the synthesis of
other pro-inﬂammatory cytokines such as IL-6 and IL-86 and con-
tributes to loss of the cartilage matrix7. Indeed, it induces the syn-
thesis ofMatrixmetalloproteinases (MMPs) andother proteinases by
chondrocytes and suppresses cartilage anabolism by inhibiting the
synthesis of proteoglycans and type II collagen8. IL-6 levels in the
synovial ﬂuid are related to the OA stage9, and they contribute to
cartilage degradation in OA10. Moreover, IL-6 could facilitate the
excitatory action of substance P on dorsal root ganglion neurons11.
Vascular endothelial growth factor (VEGF) and its receptors are
expressed inOAcartilageandthe synovial pannus andare involved in
the angiogenesis associated with cartilage destruction during OA12.
MAP kinase (MAPK) pathways playa signiﬁcant role in inﬂammation
and OA. It has been demonstrated that MAPK pathways are able to
modulate cytokine-induced chondrocyte responses13.
Certain therapies that speciﬁcally interfere with the expression
or actions of pro-inﬂammatory cytokines have been explored14,15.
nonsteroidal anti-inﬂammatory drugs (NSAIDs) have analgesic,
antipyretic and anti-inﬂammatory properties and are extensively
prescribed for several musculoskeletal disorders. Indeed, the
Osteoarthritis Research Society International (OARSI) recently rec-
ommended the use of NSAIDs for management of knee and hip OA
in symptomatic patients16. These drugs have been shown to inﬂu-
ence cytokine metabolism in the synovial ﬂuid of OA patients with
satisfactory relief of painful osteoarthritic joints17e19.
The aim of the current study was to explore whether selected
NSAID treatment inhibits TNF-alpha, IL-6, IL-8, and VEGF secretion
in the synovial ﬂuid of osteoarthritic joints. Diclofenac, ibuprofen
and celecoxib were studied. Under the hypothesis that relation-
ships between pro-inﬂammatory cytokines and the clinical status
of OA patients are possible, we also evaluated the association be-
tween the concentration of these molecules in the osteoarthritic
knee synovial ﬂuid and the pain and functional status of patients
with OA. The effects of selected NSAIDs on signal transduction
pathways in the synovial membrane were also investigated.
Materials and methods
Study population
From April 2010 to August 2011, 128 patients were evaluated at
the Department of Orthopaedic and Trauma Surgery of the Magna
Græcia University (Catanzaro, Italy) for primary knee OA and
scheduled for a total knee arthroplasty (TKA). Patients eligible for
this randomized, open label, parallel-group, single center study
should be older than 50 years and should have primary knee OA
diagnosed according to the clinical and radiological criteria of the
American Rheumatism Association20. Further inclusion criteria
were clinical signs of joint inﬂammation (warmth, swelling or
effusion) and a disease severity grade 2 or 3 according to the
KellgreneLawrence (KL) classiﬁcation21.
Patients who met the following conditions were excluded: al-
lergy to NSAIDs, progressive serious medical conditions (such as
cancer, AIDS or end-stage renal disease), history of gastrointestinal
ulcer or bleeding, a hemoglobin concentration lower than 11.5 g/dL,
renal diseases (serum creatinine concentration more than 1.2 times
the upper limit of the normal range according to the central labo-
ratory deﬁnition reference values), or liver dysfunction (serumalanine or aspartate transaminase concentrations more than 1.5
times the upper limit of normal range according to the central
laboratory deﬁnition reference values). Other exclusion criteria
were a diagnosis of rheumatoid arthritis based on the physical
examination and laboratory data, alcohol consumption (consuming
>3 alcoholic beverages daily) and substance abuse, anticoagulant
treatment and inability to give informed consent. Patients were
also excluded if theywere currently, or within the 3months prior to
inclusion, being treated with corticosteroids or indomethacin. Pa-
tients who received intra-articular treatment with corticosteroids
or hyaluronic acid within 6months preceding the study or systemic
NSAIDs within 15 days before the study were also excluded. Finally,
patients with other painful conditions, or on medication that could
possibly confound the evaluation of pain relief (i.e., opioids, para-
cetamole, corticosteroids, antiepileptics, benzodiazepines and an-
tidepressants), were also excluded.
This study was approved by the Researchers Ethics Committee
(number 2010.29) and was conducted in accordance with the
Declaration of Helsinki and the Guideline for Good Clinical Practice.
All of the participants signed written informed consent prior to
enrollment.
Experimental protocol
In this study the eligible patients were randomized into six
study groups for treatment (all of the groups consisted of 15 pa-
tients), and for 2 weeks an oral dose of the following NSAIDs were
given: diclofenac slow release 75 mg/once day or 75 mg/bid
(Novartis Pharmaceuticals UK Ltd, Camberley, UK); ibuprofen
600 mg/bid or 600 mg/tid (Abbott laboratories SPA, Campoverde
Latina, Italy); or celecoxib 200 mg/once day or 200 mg/bid (Pﬁzer
Inc, New York, NY, USA) (Fig. 1). The patients were allocated using a
randomized list produced by a computer-generated table in order
to ensure that there were no relevant differences among the study
groups with respect to age, sex, OA stage and The Western Ontario
and McMaster universities (WOMAC) score.
Clinical assessment
WOMAC osteoarthritis index score was used to measure the
disease-speciﬁc health status of patients before and after the
pharmacological treatment22. The WOMAC is a self-administered
validated outcome measure that evaluates pain (ﬁve items), stiff-
ness (two items), and physical function (17 items). A total WOMAC
summary score is calculated for each individual, adjusted, and re-
ported on a 0e100 scale. Lower scores are associated with less pain
and stiffness and better function. The safety of the study medica-
tions was assessed by monitoring for any adverse drug reactions
(ADRs), whichwere assessed for severity and causality. The severity
of ADRs was assessed by a modiﬁed Hartwig and Siegel scale that
classiﬁes the severity of an ADR as mild, moderate or severe with
various levels according to factors such as requirement for change
in treatment, duration of hospital stay, and any disability produced
by the ADR23. To evaluate the relationship between ADRs and drug
treatment, the Naranjo adverse probability scale was applied24. The
Naranjo scale consists of objective questions with three types of
responses (yes, no or do not know). The scores are given accord-
ingly and the drug reactions are classiﬁed as deﬁnite, probable or
possible.
The number, duration, and severity of pain attacks, analgesic
intake and the occurrence of adverse events were recorded in a daily
diary card 1 week prior to the start of the trial and up to 7 days after
the surgery. The total blood loss related to TKA was evaluated as
previouslydescribed25. The overall clinical responseduring the study
was assessed by physicians who were blinded to the treatment.
Fig. 1. Schematic representation of treatment groups.
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At the time of the ﬁrst admission (T0) and at surgery (T1¼14 days
after beginning of the treatment), samples of synovial ﬂuid were ob-
tained from the knee joint of patients for analysis. The ﬂuid samples
were aspirateddirectlyorobtainedby lavage, corrected fordilutionby
the urea method26 and analyzed while blinded to the clinical
information.
The synovial ﬂuid was evaluated by the Biochip Array using
dedicated evidence instrumentation and software (Randox Labora-
tories,Crumlin,UK) for simultaneousquantitativedetectionof IL-6, IL-
8, VEGF, and TNF-alpha in a 100 ml sample (supernatant). The Biochip
Array isa solid-statedevice containingarraysofdiscrete test regionsof
immobilized antibodies speciﬁc to different cytokines and growth
factors. The immune reaction is quantitated by chemiluminescence.
Increased levels of cytokine are directly related to the signal emitted.
Digital imaging technology is used to detect the signal and the con-
centration of each analyte is calculated from the calibration curve.
Cytokines in thesupernatantweredetectedaspg/ml.Theessay ranges
were 0e707 pg/ml for the TNF-alpha, 0e1063 pg/ml for IL-6, 0e
1492pg/ml for IL-8,and0e3043pg/ml forVEGF. Eachexperimentwas
performed in triplicate. All of the samples were evaluated by an
operator who was blinded to the experimental design.
Signal transduction pathways
A 2 cm2 sample of the synovial membrane was taken from each
patient treated with NSAIDS at the time of surgery. A small controlTable I
Baseline characteristics of patients
Ibuprofen
1200 mg/day
Ibuprofen
1800 mg/day
Diclofenac
75 mg/day
Dic
150
Sex
Female 8 9 10 7
Male 7 6 5 8
Age 67.3  4.9 66.1  6.8 68.4  3.6 67.
(55e73) (53e78) (63e75) (59
OA stage
2 7 6 8 9
3 8 9 7 6
T0 WOMAC 60  8.8 60.9  7.8 62.1  6.8 59.
(47e65) (46e77) (43e69) (45group of patients (n¼ 10) with knee OAwhowere subjected to TKA
were also enrolled in the study. These patients fulﬁlled the same
inclusion and exclusion criteria of the patients randomized into the
groups of treatment and they did not receive any NSAID treatment
before surgery. The control group did not differ for sex, age and OA
stage in comparison with the groups of treatment (Table I). Each
synovial membrane was lysed in Thermo Scientiﬁc T-PER Tissue
Protein Extraction Reagent (Thermo Scientiﬁc Inc, Waltham, MA,
USA) that was enriched with both protease and phosphatase in-
hibitors. The protein extracts were then separated as previously
described27.
Immunoblotting was performed using anti-phospho-c-Jun
N-terminal kinases (JNK), anti-phospho-p38, anti-phospho-
extracellular signal-regulated kinases (ERK)1/2, and anti-
phospho-RAS monoclonal antibodies (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) as previously described28. To normalize
for protein loading, after being stripped the membranes that were
probed with anti-phospho-ERK1/2 were re-probed with polyclonal
antibodies against total (phosphorylated and unphosphorylated)
ERK1/2 (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA). The
membranes probed with anti-phospho-JNK, anti-phospho-p38,
and anti-phospho-RASmonoclonal antibodies were re-probedwith
an anti g-tubulin monoclonal antibody (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA). The blots were also incubated with a
mouse monoclonal caspase-3 (E-8) antibody, directed against both
inactive pro-caspase-3 and active caspase-3, a common enzymatic
marker of apoptosis. Again, in order to normalize for protein
loading, the membranes were re-probed with an anti g-tubulinlofenac
mg/day
Celecoxib
200 mg/day
Celecoxib
400 mg/day
Control p
11 9 6 0.596
4 6 4
3  4.8 69.1  6.3 63.5  4 68  4.8 0.094
e78) (59e81) (57e72) (63e74)
5 7 5 0.606
10 8 5
3  6.9 60.2  8.6 62.4  7.4 n.a. 0.865
e71) (45e78) (49e72)
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CA, USA). Antibody binding was visualized by enhanced chem-
iluminescence (ECL-Plus, Amersham Pharmacia Biotech, Piscat-
away, NJ, USA). The intensities of the experimental bands were
analyzed by computer-assisted densitometry as previously
described29 and expressed as arbitrary units (AU).
All of these experiments were performed in triplicate by an
operator who was blinded to the experimental design.
Sample size and statistical analysis
The primary outcome for the power calculation was an
improvement in the WOMAC score.
As previously described, a 17% WOMAC score difference was
considered to be the minimal clinical improvement threshold that
was important from the subject’s perspective30. To detect a clinically
relevant difference between each group 90 subjects are needed
(power >85%, alpha 0.05, two-tailed). Regarding the effects on the
synovial concentration of cytokines, we were unable to deﬁne a
clinically signiﬁcant reduction or to determine a power calculation.
In this light, these results could only be labeled as exploratory.
The mean, standard deviation and range were reported for the
continuous variables, whereas the counts described the categorical
variables. Data were checked for normality using the Kolmogorove
Smirnov test. The Student’s t test and the c2 test were used when
appropriate to test the signiﬁcance of the differences. The analysis
of variance (ANOVA) was used to evaluate the differences between
multiple means. Once we determined that differences existed, a
Bonferroni test was used to determine which means differed. An
age-adjusted univariate linear and logistic regression analysis was
used to evaluate the relationship between the explanatory vari-
ables and the outcomes. Explanatory and confounding variables
included in the analysis were: age (continuous), gender (categori-
cal), radiological OA classiﬁcation (discrete), body mass index (BMI)
(continuous), baseline WOMAC score (continuous), baseline cyto-
kine concentration (continuous). WOMAC score at follow-up
(continuous), WOMAC score variation (continuous), baseline cyto-
kine concentration (continuous), cytokine concentration at follow-
up (continuous), variation of cytokine concentration (continuous),
and ADRs (continuous) were treated as outcomes and the effect of
possible predictors was checked for their value. A P value of less
than 0.05 was considered statistically signiﬁcant. The SPSS (SPSS
Inc., Chicago, USA) and G*Power (Institut für Experimentelle Psy-
chologie, Heinrich Heine Universität, Dusseldorf, Germany) soft-
ware were used for the statistical analyses.Fig. 2. Effects of NSAIDs on WOMAC score. All values are expressed means  standard devi
values at T1 and T0.Results
Disease-speciﬁc quality of life
After a detailed clinical history and radiological examination, 90
patients, 54 women (67.2  5.1 years) and 36 men (66.31  4.8
years), with a mean body mass index of 34.5  3.7 (men
33.5 3.52; women 34.4 3.9) were recruited in this trial. Patients’
data are shown in Table I.
The differences in the WOMAC index at T0 were not statisti-
cally signiﬁcant between the groups. No patients were lost to
follow-up and the WOMAC score variation after NSAID treatment
for the groups of patients is shown in Fig. 2. All of the NSAIDs
improved the WOMAC scores, and the degree of improvement
was greater at higher dosages of drugs (P < 0.001). Ibuprofen
1800 mg/day exhibited a higher WOMAC score improvement
with respect to celecoxib 200 mg (95% CI: 5.8e8.8, P < 0.001),
but not compared to celecoxib 400 mg/day (95% CI: 1.04 to
2.84, P ¼ 0.351). The effects of celecoxib 400 mg on the WOMAC
score variation was signiﬁcantly higher in comparison to diclo-
fenac 150 mg (95% CI: 0.15e4.49, P ¼ 0.037); conversely, no
signiﬁcant differences were noted between ibuprofen 1800 mg
and diclofenac 150 mg (95% CI: 0.43 to 2.83, P ¼ 0.143). The
effects of each NSAID were independent of the age of enrolled
patients. In all but two groups the WOMAC score variation did
not differ according to gender (Supplementary data).
Synovial ﬂuid cytokines
Synovial ﬂuid samples were obtained from all of the patients in
the study. No out of range values were found. On the whole, NSAID
treatment induced a dose-dependent reduction of pro-
inﬂammatory cytokines without differences between the
different NSAIDs. Higher dosages of diclofenac, ibuprofen and cel-
ecoxib were associated with a greater reduction of IL-6, VEGF and
TNF-alpha synovial ﬂuid concentrations (Figs. 3e5) in comparison
to the lower dosages. NSAID treatment did not signiﬁcantly modify
IL-8 synovial concentration with any drug at any dose (data not
shown). In the whole study population of 90 individuals, a direct
correlation between the concentration at T1 of most of the mole-
cules evaluated in the synovial ﬂuid and an improvement in the
total WOMAC was noted (WOMAC vs IL-6: b ¼ 0.914, P ¼ 0.005;
WOMAC vs VEGF: b: 0.985, P ¼ 0.008; WOMAC vs TNF-alpha:
b ¼ 0.975, P < 0.001). No statistically signiﬁcant correlations were
noted between the concentration of cytokines or VEGF at T0 or theiration for each treatment group (n ¼ 15) and were evaluated as difference between the
Fig. 3. IL-6 concentrations in synovial ﬂuid before (T0) and after NSAID treatment for 14 days (T1) (n ¼ 15) for each group.
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the knee joint (KL grade 2 vs KL grade 3, Supplementary data).
Signal transduction pathways
The effect of NSAID on signal transduction pathways was tested
only at the highest dosage. NSAID treatment induced a statistically
signiﬁcant (P < 0.01) inhibition of ERK, JNK, p38 and RAS phos-
phorylation (Fig. 6) along with caspase-3 activation (Fig. 7) with
respect to the control patients.
NSAID safety
A higher postoperative blood loss was recorded in two women
treated with ibuprofen (1800 mg/day) (mean blood loss:
945  115 mL) and in two women and one man treated with
diclofenac (150 mg/day) (mean blood loss: 915  120 mL) in
comparison to the average values of the remaining patients (mean
blood loss: 580  270 mL). Two further other patients treated with
ibuprofen 1800 mg/day experienced nausea 4 days after beginning
the drug. The ADRs were categorized as probable based on the
modiﬁed Hartwig and Siegel scale of severity assessment, and the
reactions were categorized as “mild level 1” severity.
Discussion
Themajor aims in OAmanagement are to provide pain relief and
to facilitate rehabilitation and return to normal function31,32. OneFig. 4. VEGF concentrations in synovial ﬂuid before (T0) and aftepossible therapeutic strategy may be inhibition of inﬂammatory
activity in the synovial tissue through NSAID administration17.
In this study we have shown that diclofenac, ibuprofen and
celecoxib used for OA treatment decrease IL-6, TNF-alpha and VEGF
in the synovial ﬂuid of the osteoarthritic joint with a parallel
improvement in joint pain and function of patients. This is the ﬁrst
study looking at the effects of diclofenac and ibuprofen on the sy-
novial ﬂuid levels of IL-6 in patients with knee OA. In a previous
study, after 14 days of treatment with celecoxib or nimesulide a
signiﬁcant reduction in the IL-6 levels was observed in the synovial
ﬂuid of patients with knee OA17. Similarly, Schumacher et al.18
demonstrated that IL-6 levels decrease in the synovial ﬂuid of
osteoarthritic patients after twoweeks of oral etodolac. The NSAID-
induced reduction of the IL-6 concentration may be explained at
least in part by inhibition of prostaglandin (PG) production by
NSAIDs. Indeed, even though some of the NSAIDs developed in
recent years show greater activity against cyclooxygenase (COX)-2,
all NSAIDs inhibit the different isoforms of COX. These enzymes
promote the synthesis of PGE2 and other prostaglandins through
the conversion of arachidonic acid. It has been previously demon-
strated that prostaglandins stimulate the production of IL-6 by
bone cells33. This hypothesis is in agreement with the observation
that OA patients treated with celecoxib exhibit decreased IL pro-
duction in the gastric mucosa34. Therefore, the effect of NSAIDs on
the IL-6 concentration is unlikely to be tissue speciﬁc. Interestingly,
it has been previously reported that celecoxib is able to decrease
TNF-alpha and PGE2 in the synovial membrane and ﬂuid, respec-
tively, after a 3-month treatment in patients with knee OA19. Theser NSAID treatment for 14 days (T1) (n ¼ 15) for each group.
Fig. 5. TNF-alpha concentrations in synovial ﬂuid before (T0) and after NSAID treatment for 14 days (T1) (n ¼ 15) for each group.
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at the effect of NSAID treatment on the VEGF synovial ﬂuid con-
centration. The current study demonstrates that all of the tested
NSAIDs are able to decrease VEGF synovial ﬂuid levels in patientsFig. 6. Effects of celecoxib (400 mg/day), diclofenac (150 mg/day) and ibuprofen (1800 m
phosphorylation in enrolled patients compared to control patients. Densitometric evaluation
n ¼ 15 in each NSAID group; n ¼ 10 in control group.with OA. Notably, it has been previously documented that VEGF
expression by the chondrocytes is increased in OA, and these levels
correlate with the degree of OA35. In agreement with previous
ﬁndings17, in the current study no tested NSAID affected IL-8g/day) for 14 days on JNK (panel A), p38 (panel B), ERK (panel C), and RAS (panel D)
of western blots is expressed as arbitrary units. Values are means  standard deviation,
Fig. 7. Effects of celecoxib (400 mg/day), diclofenac (150 mg/day) and ibuprofen (1800 mg/day) for 14 days on caspase-3 activation in enrolled patients compared to control
patients. The part of the blot in the MW range between 14 and 20 kDa is shown in order to visualize the active, cleaved form of caspase-3. Densitometric evaluation of western blots
is expressed in arbitrary units. Values are means  standard deviation, n ¼ 15.
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secretion of this cytokine during OA is likely to be regulated by
different pathways.
Unsurprisingly, we documented a greater reduction in the IL-6,
VEGF and TNF-alpha levels after treatment with higher NSAID
dosages, in particular with ibuprofen and celecoxib. Classical
NSAIDs have been correlated with gastrointestinal, cardiovascular
and renal events36. We only observed increased bleeding in some of
the patients treated with ibuprofen and diclofenac at higher dos-
ages. The absence of serious ADRs in our study could be related to
several factors such as the short treatment time (14 days) and the
exclusion of patients with a history of gastrointestinal, cardiovas-
cular, renal and liver diseases.
In the current study, the NSAID treatment induced a statistically
signiﬁcant inhibition of ERK, JNK, p38 and RAS phosphorylation
along with caspase-3 activation in the synovial membrane of OA
patients with respect to the controls. As far as we know, this effect
has never been described previously. Indeed, it was demonstrated
that NSAIDs inactivateMAPKs in the articular cartilage37,38 but their
effect on the synovial membrane was not evaluated. The possibility
that the inhibition of MAPKs results from the decreased levels of
cytokines induced by NSAID treatment cannot be ruled out. Indeed,
it was reported in a transgenic mouse model that TNFa enhances
chronic inﬂammation of the synovial membrane by activation of
MAPK cascade39. It is tempting to speculate that the high levels of
MAPK activationwe have observed in control patients inﬂuence the
progression of OA and that the inhibition of MAPKs after NSAID
treatment (Fig. 6) correlates with the effects of NSAIDs on WOMAC
score (Fig. 2). Indeed, MAPK activity plays a key role in the regu-
lation ofMMPs production by chondrocytes13 and it may contribute
to the development of OA through down regulation of peroxisome
proliferators-activated receptor gamma40 and up regulation of
inducible NO synthase41.
We next demonstrated that the WOMAC scores signiﬁcantly
improved after diclofenac, celecoxib or ibuprofen treatment. This is
in agreement with recent papers showing that celecoxib and
ibuprofen are able to improveWOMAC scores in patients with knee
OA42,43. This effect could be related to the ability of NSAID treat-
ment to reduce synovitis and joint effusion due to degenerativechanges in the osteoarthritic joint. Interestingly, a signiﬁcant cor-
relation between the plasma CRP levels and synovial ﬂuid IL-6
levels or the degree of synovial inﬂammatory inﬁltration has
been documented in patients with knee OA44. A direct association
between improvement in the total WOMAC score and the decrease
in the cytokine concentration at T1 was reported in the current
study. Apart from a correlation between PGE2 and the WOMAC
index, Brenner et al.45, failed to ﬁnd any signiﬁcant relationships
between IL-6 or TNF-alpha and any of the assessed clinical signs. On
the contrary, and in agreement with our ﬁndings, a signiﬁcant
positive correlation between the total WOMAC score and its sub-
scales with TNF-alpha in patients with OA of the knee was previ-
ously reported46. The authors noted a similar correlation between
IL-6 and the WOMAC stiffness domain.
Some weaknesses of the current study design might limit the
conclusions that can be drawn from this data. We were not able to
examine normal knees to evaluate both the cytokine levels in the
synovial ﬂuid and MAPK activation in the synovial membrane.
However, there are obvious ethical concerns in obtaining control
synovial ﬂuid and synovial membrane from intact knee joints.
Further limitations of the current study have to be acknowledged.
First, the cytokine gene expression was not evaluated and varia-
tions in these genes have been associated with different levels of
inﬂammation47. Second, we only examined the synovial ﬂuid and
not the serum levels of the cytokines. Thus, we could not report any
correlation between the serum and synovial ﬂuid levels of these
molecules. Finally, only OA patients with evidence of active joint
inﬂammation were included in this trial. Hence, we cannot be
conﬁdent that our result is applicable beyond this phenotype.
However, despite some so-called noninﬂammatory types of OA are
usually identiﬁed, inﬂammation is directly responsible for several
clinical symptoms and reﬂects the progression of the disease48.
In the current study, the question concerning the inﬂuence of
NSAIDs on the progression of structural changes in OA remains
unanswered. An association between synovial inﬂammatory pro-
cesses and OA progression has been reported, thus supporting the
use of these drugs to treat OA49,50. However, certain studies suggest
that some NSAIDs inhibit matrix synthesis by articular cartilage in
vitro51,52. There are also reports of increased rate of OA progression
L. Gallelli et al. / Osteoarthritis and Cartilage 21 (2013) 1400e1408 1407in patients receiving NSAIDs53. In this light, long-term NSAID
treatments should be discouraged in patients with OA. However,
the controversial effects of prolonged NSAID treatment in OA
overpasses the issue of this study, which evaluated the effects of
this therapy after a short-term period.
In conclusion, the current study suggests that short-term
treatment with oral celecoxib, ibuprofen and diclofenac effec-
tively suppress proinﬂammatory cytokines and improves pain and
function in patients with symptomatic knee OA without serious
adverse events. Higher dosages of the evaluated NSAIDs provide
better improvement in the disease-speciﬁc quality of life of OA
patients and a greater modulation of cytokine secretion. Further
studies looking at molecular pathways implicated in the NSAID
response during OA are warranted.
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